StreetAlpha.app
Home › Stocks › STIM

Neuronetics, Inc. (STIM)

$1.28
▲ +2.40%
LAST CLOSE · NOV 17

Neuronetics sells the NeuroStar magnetic brain stimulation system to healthcare providers for treating depression. It last closed at $1.28 on Nov 17, up 2.40% on the day. The average 12-month price target from 2 analysts is $6.00 (+368.8% from the last close), with a high of $6.00 and a low of $6.00.

AI Auto Pilots
Is STIM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$159.8M
+23.0% vs a year ago
Net income
−$23.1M
−14.4% margin
EPS (diluted)
−$0.32
Free cash flow
−$9.6M
−6.0% margin
Valuation
Market cap
$99.5M
77.7M shares
P/E
–
No P/E while losing money
Price to sales
0.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.1M
At Sep 30
Debt
$61.8M
At Sep 30
Shareholder equity
$18.7M
Shares outstanding
77.7M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $55.3M$55.3MFY2021FY2022: $65.2M$65.2MFY2022FY2023: $71.3M$71.3MFY2023FY2024: $74.9M$74.9MFY2024FY2025: $149.2M$149.2MFY2025

From STIM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated STIM in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 368.8% upside

Based on 2 analysts who set a price target on STIM in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $1.28.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $1.28
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
B. Riley SecuritiesTarget raised
Nov 6Buy$5 → $6
B. Riley SecuritiesInitiated
Sep 11Buy$5
BTIGReiterated
Sep 9Buy$6
BTIGTarget raised
Aug 11Buy$5 → $6
BTIGInitiated
Jul 20Buy$5
DateFirmActionRatingPrice target
Nov 6B. Riley SecuritiesTarget raisedBuy$5 → $6
Sep 11B. Riley SecuritiesInitiatedBuy$5
Sep 9BTIGReiteratedBuy$6
Aug 11BTIGTarget raisedBuy$5 → $6
Jul 20BTIGInitiatedBuy$5
Loading…

Technical Analysis

STIM · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 57% below its 20 day and 78% below its 50 day average. It is 46% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), near oversold. The nearest support is the Pivot S1 at $1.25, and the nearest resistance the Pivot at $1.29.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 19.3%/day
Key levels
$3.4452 week high+168.8%
$2.29100 day average+78.9%
$2.2850 day average+78.1%
$2.0120 day average+57.0%
$1.86200 day average+45.3%
$1.39Swing high (Jun 15)+8.6%
$1.32Pivot R1+3.1%
$1.29Pivot+0.8%
$1.28Last close
$1.25Pivot S1−2.3%
$1.17Swing low (Jun 23)−8.6%
$0.8052 week low−37.5%
Indicators
RSI (14)30.48Weak, oversold below 30Neutral
MACD-0.23Below its signal lineBearish
Stochastic9.2Near the bottom of its rangeOversold
ADX (14)26.1Trending down
Williams %R-92.2Oversold below −80, overbought above −20Oversold
CCI (20)-156.1Oversold below −100, overbought above 100Oversold
Rate of change−43.4%Change over 10 sessionsBearish
ATR (14)$0.25Typical daily range, 19.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for STIM

What happened before

See how STIM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow STIM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How STIM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in STIM in the last 90 days.

Loading…

See today’s whale options flow across the market →

STIM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●49 buying vs 46 selling
  • ▲Held by funds +10.0 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9587+9.2%
In funds' top 1021+100.0%
Held by funds57.9%47.9%+10.0 pts
New / increased25 / 2416 / 29+8.9%
Reduced / sold out30 / 1625 / 28−13.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See STIM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STIM is in one of them and how their past STIM trades turned out.

STIM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered STIM in an article yet. Here's the latest on the wider market.

About Neuronetics

Neuronetics is a medical technology company based in Malvern, Pennsylvania. Its main product is the NeuroStar Advanced Therapy System, a treatment given in a doctor's office that uses magnetic pulses to stimulate parts of the brain linked to mood. It is used to treat major depression and some related conditions. The company sells the system and its treatment sessions to healthcare providers, and it also runs treatment centers in the United States that offer the therapy to patients.

Headquarters
Malvern, PA
Founded
2003